Summary of the Clinical Problem
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19, a pandemic that has affected more than 400,000 individuals and caused nearly 20,000 deaths as of late March 2020. Approximately 5% to 10% of patients require intensive care unit (ICU) admission and mechanical ventilation.\(^1\)

Characteristics of the Guideline Source
The Surviving Sepsis Campaign (SSC) has previously published a series of guidelines for sepsis and septic shock. Based on this experience, experts were recruited to write guidelines on the management of COVID-19 in critically ill adults. These guidelines were authored by 36 experts from 12 countries (Table).\(^2\)

---

**GUIDELINE TITLE** Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults With COVID-19

**DEVELOPER** Surviving Sepsis Campaign (SSC)

**RELEASE DATE** March 23, 2020

**TARGET POPULATION** Critically ill adults with COVID-19

**SELECTED MAJOR RECOMMENDATIONS**

**Infection Control and Testing**
1. For health care workers performing aerosol-generating procedures (eg, endotracheal intubation, nebulized treatments, open suctioning) use of fitted respirator masks is recommended (N95 respirators, FFP2), instead of surgical masks, in addition to other personal protective equipment (PPE) (best practice statement).

2. For usual care of nonventilated patients, or for performing non–aerosol-generating procedures on patients receiving mechanical ventilation, use of medical masks is recommended, instead of respirator masks, in addition to other PPE (weak recommendation, low-quality evidence [LQE]).

3. Diagnostic lower respiratory tract samples (endotracheal aspirates) are preferred over bronchial washings, bronchoalveolar lavage, and upper respiratory tract (nasopharyngeal or oropharyngeal) samples (weak recommendation, LQE).

**Hemodynamic Support**
1. For acute resuscitation of adults with shock, the following are suggested: measuring dynamic parameters to assess fluid responsiveness (weak recommendation, LQE), using a conservative fluid administration strategy (weak recommendation, very LQE), and using crystalloids over colloids (strong recommendation, moderate QE). Balanced crystalloids are preferred over unbalanced crystalloids (weak recommendation, moderate QE).

2. For adults with shock, the following are suggested: using norepinephrine as the first-line vasoactive (weak recommendation, LQE), use of either vasopressin or epinephrine as the first line if norepinephrine is not available (weak recommendation, LQE), and using norepinephrine alone (weak recommendation, LQE).

**Ventilatory Support**
1. Starting supplemental oxygen is recommended if the SpO2 is less than 90% (strong recommendation, moderate QE). SpO2 should be maintained no higher than 96% (strong recommendation, moderate QE).

2. For acute hypoxemic respiratory failure despite conventional oxygen therapy, use of high-flow nasal cannula (HFNC) is suggested relative to conventional oxygen therapy and noninvasive positive pressure ventilation (NIPPV) (weak recommendation, LQE). If HFNC is not available, a trial of NIPPV is suggested (weak recommendation, very LQE). Close monitoring for worsening of respiratory status and early intubation if worsening occurs is recommended (best practice statement).

3. For adults receiving mechanical ventilation who have acute respiratory distress syndrome (ARDS), use of high tidal volume ventilation (6-8 mL/kg of predicted body weight) is recommended and preferred over lower tidal volumes (<8 mL/kg) (strong recommendation, moderate QE). Targeting plateau pressures of <30 cm H2O (strong recommendation, moderate QE) is recommended. Using a higher positive end-expiratory pressure (PEEP) strategy over lower PEEP strategy is suggested (weak recommendation, LQE).

4. For adults receiving mechanical ventilation who have severe ARDS and hypoxemia despite optimizing ventilation, a trial of inhaled pulmonary blocking agents (NMBAs) instead of continuous NMBA infusion to facilitate protective lung ventilation is suggested (weak recommendation, LQE).

5. For adults receiving mechanical ventilation who have severe ARDS and hypoxemia despite optimizing ventilation, a trial of inhaled pulmonary blocking agents (NMBAs) instead of continuous NMBA infusion to facilitate protective lung ventilation is suggested (weak recommendation, LQE).

**Therapy**
1. In adults receiving mechanical ventilation who do not have ARDS, routine use of systematic corticosteroids is suggested against (weak recommendation, LQE). In those with ARDS, use of corticosteroids is suggested (weak recommendation, LQE).

2. In COVID-19 patients receiving mechanical ventilation who have respiratory failure, use of empiric antimicrobial/antibacterial agents is suggested (no evidence rating; assess for deescalation).

3. In critically ill adults with fever, use of pharmacologic agents for temperature control is suggested over nonpharmacologic agents or no treatment. Routine use of standard IV immunoglobulin is not suggested. Convalescent plasma is not suggested. There is insufficient evidence to issue a recommendation on use of any of the following: antiviral agents, recombinant interferons, chloroquine/hydroxychloroquine, or tocilizumab.
Evidence Base

The GRADE method was used, with the actionable guideline questions placed in population, intervention, comparator, outcomes (PICO) format. The first discusses PPE to protect health care workers and prevent nosocomial spread of virus. A recent clinical trial of 2862 health care personnel at 137 outpatient sites compared the use of N95 respirators vs medical masks and found no significant difference in the incidence of laboratory-confirmed influenza (8.2% vs 7.2% health care personnel seasons; difference, 1.0% [95% CI, −0.5% to 2.5%]; P = .18) (adjusted odds ratio, 1.18 [95% CI, 0.95−1.45]).3 The CDC recently discussed strategies for optimizing the supply of face masks. Critically ill patients with COVID-19 often develop septic (distributive) shock. Fluid resuscitation guided by dynamic assessment of fluid responsiveness is recommended based on a reduction in mortality (risk ratio, 0.59 [95% CI, 0.42−0.83]; P = .002) in a meta-analysis of 1652 patients in 13 trials.4 These dynamic measures facilitate a more judicious, rather than liberal, fluid strategy both during and after initial resuscitation.5

Benefits and Harms

The panel issued a suggestion against the routine use of systemic corticosteroids for respiratory failure without ARDS in COVID-19, but issued a suggestion for use in patients with ARDS. One retrospective, non-peer-reviewed report of 46 patients6 suggested treatment with methylprednisolone, 1 to 2 mg/kg/d for 5 to 7 days, was associated with a reduction in duration of fever and the need for supplemental oxygen. The panel also drew on indirect evidence of corticosteroid use in community-acquired pneumonia, ARDS, and other viral infections, using a Cochrane review7 on the use of steroids in viral pneumonia, updated to include 15 cohort studies on influenza and 10 on coronaviruses. This analysis found an association between corticosteroid use and increased mortality (odds ratio, 2.76 [95% CI, 2.06−3.69]), although the association among patients with coronaviruses was unclear (odds ratio, 0.83 [95% CI, 0.32−2.17]).

The guideline recommendations for management of respiratory failure highlight the competing goals unique to the COVID-19 pandemic. A recommendation for the use of HFNC oxygen therapy is based on findings from a clinical trial that showed a benefit relative to standard oxygen and NIPPV in progression to intubation.8 The panel also recommended a trial of NIPPV if HFNC is unavailable or ineffective. Following these recommendations may prevent intubation and the need for ventilator support, a scarce resource when there are large numbers of COVID-19 cases. However, HFNC and NIPPV may also aerosolize respiratory droplets, which will increase the need for negative-pressure rooms and N95 or FFP2 masks, which are also a scarce resource.

Discussion

The COVID-19 pandemic has brought unprecedented challenges regarding the ability to generate timely evidence, even as the disease overwhelms health care systems and stresses the clinical workforce. This SSC guideline2 will be frequently updated online as global evidence accrues, but it reflects the central tenants of best practices for ARDS: low tidal volume strategy, PEEP titration, avoidance of hyperoxia, and a conservative fluid strategy.

Areas in Need of Future Study or Ongoing Research

Many of these recommendations are extrapolated from studies and experience in critically ill patients without COVID-19. However, this pandemic has necessitated flexibility and ingenuity to address its unique challenges, and it will require continued rapid and judicious synthesis of heterogeneous and rapidly evolving data and clinical experience shared by clinicians.

For instance, concern for aerosolization with HFNC and NIPPV and a critical shortage of mechanical ventilators have led to consideration of helmet NIPPV as an alternative in centers with this resource. Additionally, a small single-center clinical trial (n = 83 patients) has suggested decreased intubation and mortality with use of helmet NIPPV compared with face mask.9 Unfortunately, these investigations used a ventilator to deliver helmet NIPPV. If the intent is to spare patients from invasive mechanical ventilation while limiting exposure to health care workers, helmet NIPPV using a ventilator may be an option. Alternatively, if mechanical ventilators are in short supply, it is possible to deliver helmet NIPPV using a flow generator (>=60 L/min) to deliver oxygen and an expiratory pressure valve to maintain PEEP. The guideline panel noted the option of helmet NIPPV but was not able to make a recommendation, noting uncertainty about its safety and efficacy in COVID-19.

Areas in Need of Future Study or Ongoing Research

Many of these recommendations are extrapolated from studies and experience in critically ill patients without COVID-19. However, this pandemic has necessitated flexibility and ingenuity to address its unique challenges, and it will require continued rapid and judicious synthesis of heterogeneous and rapidly evolving data and clinical experience shared by clinicians.

For instance, concern for aerosolization with HFNC and NIPPV and a critical shortage of mechanical ventilators have led to consideration of helmet NIPPV as an alternative in centers with this resource. Additionally, a small single-center clinical trial (n = 83 patients) has suggested decreased intubation and mortality with use of helmet NIPPV compared with face mask.9 Unfortunately, these investigations used a ventilator to deliver helmet NIPPV. If the intent is to spare patients from invasive mechanical ventilation while limiting exposure to health care workers, helmet NIPPV using a ventilator may be an option. Alternatively, if mechanical ventilators are in short supply, it is possible to deliver helmet NIPPV using a flow generator (>=60 L/min) to deliver oxygen and an expiratory pressure valve to maintain PEEP. The guideline panel noted the option of helmet NIPPV but was not able to make a recommendation, noting uncertainty about its safety and efficacy in COVID-19.

Finally, there is a pressing need to address resource allocation, innovative staffing, and alternative delivery models in providing ethical care for critically ill patients when there are insufficient ICU beds during a pandemic.10

Table. Guideline Rating

<table>
<thead>
<tr>
<th>Standard</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Establishing transparency</td>
<td>Good</td>
</tr>
<tr>
<td>Management of COI in the guideline development group</td>
<td>Good</td>
</tr>
<tr>
<td>Guideline development group composition</td>
<td>Good</td>
</tr>
<tr>
<td>Clinical practice guideline-systematic review intersection</td>
<td>Good</td>
</tr>
<tr>
<td>Establishing evidence foundations and rating strength for each of the guideline recommendations</td>
<td>Good</td>
</tr>
<tr>
<td>Articulation of recommendations</td>
<td>Good</td>
</tr>
<tr>
<td>External review</td>
<td>Fair</td>
</tr>
<tr>
<td>Updating</td>
<td>Good</td>
</tr>
<tr>
<td>Implementation issues</td>
<td>Good</td>
</tr>
</tbody>
</table>

Related resources

JAMA Network Coronavirus Resource Center

© 2020 American Medical Association. All rights reserved.
ARTICLE INFORMATION

Author Affiliations: Pulmonary and Critical Care, University of Chicago, Chicago, Illinois (Poston, Patel); General Internal Medicine, University of Chicago, Chicago, Illinois (Davis).

Corresponding Author: Jason T. Poston, MD, University of Chicago, 850 E 58th St, Chicago, IL 60615 (Jason.Poston@uchospitals.edu).

Section Editor: Edward H. Livingston, MD, Deputy Editor, JAMA.

Published Online: March 26, 2020. doi:10.1001/jama.2020.4914

Conflict of Interest Disclosures: Dr Patel reports receiving grants from Parker B. Francis Career Development award and from NIH/NHLBI T32 HL007605 Research Training in Respiratory Biology. Dr Poston receiving honoraria for the CHEST Critical Care Board Review Course. Dr Davis reported no disclosures.

REFERENCES


